{"id":"https://openalex.org/W2581817452","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.tps8109","title":"TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.","display_name":"TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2581817452","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.tps8109","mag":"2581817452"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.tps8109","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.tps8109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.tps8109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055074037","display_name":"James Chih\u2010Hsin Yang","orcid":"https://orcid.org/0000-0002-5586-5138","observed_orcids":["https://orcid.org/0000-0002-5586-5138"]},"institutions":[{"id":"https://openalex.org/I16733864","display_name":"National Taiwan University","ror":"https://ror.org/05bqach95","country_code":"TW","type":"education","lineage":["https://openalex.org/I16733864"]},{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"James Chih-Hsin Yang","raw_affiliation_strings":["Department of Oncology, National Taiwan University Hospital; Graduate Institute of Oncology & Cancer Research Center, National Taiwan University, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, National Taiwan University Hospital; Graduate Institute of Oncology & Cancer Research Center, National Taiwan University, Taipei, Taiwan","institution_ids":["https://openalex.org/I16733864","https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048231332","display_name":"Sanjay Popat","orcid":"https://orcid.org/0000-0003-2087-4963","observed_orcids":["https://orcid.org/0000-0003-2087-4963"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sanjay Popat","raw_affiliation_strings":["Royal Marsden Hospital, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Marsden Hospital, London, United Kingdom","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043589689","display_name":"Panos G. Georgiou","orcid":"https://orcid.org/0000-0002-5479-5932","observed_orcids":["https://orcid.org/0000-0002-5479-5932"]},"institutions":[{"id":"https://openalex.org/I4210154258","display_name":"Clovis Oncology (United Kingdom)","ror":"https://ror.org/04j2fjp47","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210151488","https://openalex.org/I4210154258"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Panos Georgiou","raw_affiliation_strings":["Clovis Oncology, Inc, Chelmsford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clovis Oncology, Inc, Chelmsford, United Kingdom","institution_ids":["https://openalex.org/I4210154258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003608301","display_name":"Emiko Miyamoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151488","display_name":"Clovis Oncology (United States)","ror":"https://ror.org/04ps4d441","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151488"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emiko Miyamoto","raw_affiliation_strings":["Clovis Oncology, Inc, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clovis Oncology, Inc, San Francisco, CA","institution_ids":["https://openalex.org/I4210151488"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021513045","display_name":"Jeffrey D. Isaacson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151488","display_name":"Clovis Oncology (United States)","ror":"https://ror.org/04ps4d441","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151488"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey D. Isaacson","raw_affiliation_strings":["Clovis Onc, Boulder, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clovis Onc, Boulder, CO","institution_ids":["https://openalex.org/I4210151488"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035640724","display_name":"Heather A. Wakelee","orcid":"https://orcid.org/0000-0003-1136-980X","observed_orcids":["https://orcid.org/0000-0003-1136-980X"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather A. Wakelee","raw_affiliation_strings":["Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"TPS8109","last_page":"TPS8109"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rociletinib","display_name":"rociletinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.8389999866485596},{"id":"https://openalex.org/keywords/t790m","display_name":"T790M","score":0.847000002861023},{"id":"https://openalex.org/keywords/platinum-based-doublet-chemotherapy","display_name":"platinum-based doublet chemotherapy","score":0.7760000228881836},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6990000009536743},{"id":"https://openalex.org/keywords/conventional-chemotherapy","display_name":"cytotoxic chemotherapy","score":0.734000027179718},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.8379999995231628},{"id":"https://openalex.org/keywords/egfr-activating-mutations","display_name":"EGFR activating mutations","score":0.5249999761581421},{"id":"https://openalex.org/keywords/asian-patients","display_name":"Asian patients","score":0.3840000033378601},{"id":"https://openalex.org/keywords/ecog-performance-status","display_name":"ECOG performance status","score":0.6600000262260437},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.33500000834465027}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8871971368789673},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.7642678022384644},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6439834833145142},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.630926787853241},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6072545051574707},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5392903089523315},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.46935921907424927},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4531860053539276},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.45267271995544434},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.407741904258728},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3111279606819153},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.2435399889945984},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.19193989038467407},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.tps8109","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.tps8109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.tps8109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2891315685","https://openalex.org/W2770635075","https://openalex.org/W2603559625","https://openalex.org/W3096198440","https://openalex.org/W2502753163","https://openalex.org/W2048478480","https://openalex.org/W2126177831","https://openalex.org/W2307503596","https://openalex.org/W4301486820","https://openalex.org/W2891328671"],"abstract_inverted_index":{"TPS8109":[0],"Background:":[1],"Rociletinib":[2],"is":[3,41,47,64,233,291],"a":[4,31,61,84,90,145,158],"small":[5],"molecule":[6],"inhibitor":[7],"that":[8,39],"selectively":[9],"targets":[10],"mutant":[11],"EGFR":[12,78,163,175],"and":[13,24,46,54,80,89,105,111,114,170,177,225,249,263],"has":[14,36],"been":[15],"shown":[16],"in":[17,50,73,144],"preclinical":[18],"studies":[19],"to":[20,66,186,205,257],"inhibit":[21],"L858R,":[22],"del19":[23],"T790M":[25,56,103],"while":[26],"sparing":[27],"wild-type":[28],"EGFR.":[29],"TIGER-X,":[30],"phase":[32,146],"1/2":[33],"dose-ranging":[34],"trial,":[35],"provided":[37],"evidence":[38,156],"rociletinib":[40,70,188],"associated":[42],"with":[43,52,102,122,133,160,173,294],"durable":[44],"response":[45,117,241],"well":[48],"tolerated":[49],"pts":[51,74,101,293],"NSCLC":[53],"positive":[55,104],"status":[57,107,221],"following":[58],"progression":[59,135,203],"on":[60,109,136,284],"TKI.1":[62],"TIGER-3":[63,98],"designed":[65],"investigate":[67],"single":[68,192],"agent":[69,193],"vs":[71,223,228],"chemotherapy":[72,195],"who":[75],"have":[76,154],"failed":[77],"therapy":[79,140],"platinum-based":[81],"doublet":[82,179],"chemotherapy;":[83],"setting":[85],"of":[86,94,116,157,216,244,277,300],"acquired":[87],"resistance":[88],"high":[91],"unmet":[92],"need":[93],"targeted":[95],"therapeutic":[96],"options.":[97],"will":[99,141,182,209,254,268,279],"evaluate":[100],"negative":[106],"based":[108,283],"blood":[110],"tumor":[112,159],"tissues,":[113],"biomarkers":[115],"or":[118,124,128,191,214],"resistance.":[119],"Methods:":[120],"Pts":[121,152,181,208],"histologically":[123],"cytologically":[125],"confirmed":[126],"metastatic":[127],"unresectable":[129],"locally":[130],"advanced":[131],"NSCLC,":[132],"radiological":[134],"the":[137,264],"most":[138],"recent":[139],"be":[142,183,210,269,280],"enrolled":[143],"3,":[147],"randomized,":[148],"open-label":[149],"study":[150,295],"(NCT02322281).":[151],"must":[153],"documented":[155],"\u2265":[161],"1":[162],"activating":[164],"mutations":[165],"excluding":[166],"exon":[167],"20":[168],"insertion,":[169],"prior":[171],"treatment":[172],"an":[174],"TKI":[176],"platinum-containing":[178],"chemotherapy.":[180],"randomized":[184],"1:1":[185],"receive":[187],"twice":[189],"daily":[190],"cytotoxic":[194],"(investigator":[196],"choice":[197],"specified":[198],"before":[199],"randomization)":[200],"until":[201],"disease":[202,246],"according":[204],"RECIST":[206],"1.1.":[207],"stratified":[211,261],"by":[212,298],"presence":[213],"absence":[215],"brain":[217],"metastases,":[218],"ECOG":[219],"performance":[220],"(0":[222],"1),":[224],"race":[226],"(Asian":[227],"non-Asian).":[229],"The":[230,260],"primary":[231],"endpoint":[232],"progression-free":[234],"survival":[235],"(PFS).":[236],"Secondary":[237],"endpoints":[238],"include":[239],"objective":[240],"rate,":[242,248],"duration":[243],"response,":[245],"control":[247],"overall":[250],"survival.":[251],"Kaplan-Meier":[252],"methodology":[253],"assess":[255],"time":[256],"event":[258,287],"variables.":[259],"log-rank":[262],"hazard":[265],"ratio":[266],"(HR)":[267],"used":[270],"for":[271],"comparing":[272],"PFS":[273],"distributions.":[274],"Serial":[275],"assessment":[276],"safety":[278],"carried":[281],"out":[282],"standard":[285],"adverse":[286],"reporting.":[288],"Planned":[289],"enrolment":[290],"600":[292],"start":[296],"planned":[297],"end":[299],"May":[301],"2015.":[302],"Sequist":[303],"LV":[304],"J":[305],"Clin":[306],"Oncol.":[307],"2014":[308],"Clinical":[309],"trial":[310],"information:":[311],"NCT02322281.":[312]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2017-02-03T00:00:00"}